Novo Nordisk Q4 Profit Beats Expectations, Sees Slower Growth in 2025

Reuters
05 Feb

LONDON/COPENHAGEN, Feb 5 (Reuters) - Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with market expectations as the pace of ferocious demand for its wildly popular obesity drug Wegovy eases somewhat.

The Danish company said it expects sales growth in local currencies to range between 16% and 24%, less than the 26% growth seen in 2024. That compares with analysts expectations of just under 20%.

The company is also grappling with competition from Eli Lilly.

It said fourth-quarter operating profit jumped 37% to 36.7 billion Danish crowns ($5.12 billion), better than the 33.6 billion forecast by analysts in a company poll.

It predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

During the fourth quarter, sales of Wegovy more than doubled to 19.9 billion crowns from 9.6 billion a year ago, in line with expectations and more than the 17.3 billion crowns achieved in the third quarter.

US-listed shares of Novo Nordisk jumped 5.4% in overnight trading.

($1 = 7.1674 Danish crowns)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10